Off label Administration of Buprenorphine in the Treatment of Major DepressionJamshid Ahmadi*
Department of Psychiatry, Hafez Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
- *Corresponding Author:
- Jamshid Ahmadi
Department of Psychiatry
Hafez Hospital, Shiraz University of Medical Sciences
Tel: +98 71 3626 3193
E-mail: [email protected]
Received date: January 12, 2017; Accepted date: January 25, 2017; Published date: January 30, 2017
Citation: Ahmadi J (2017) Off label Administration of Buprenorphine in the Treatment of Major Depression. J Depress Anxiety 6:263. doi:10.4172/2167-1044.1000263
Copyright: © 2017 Ahmadi J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Buprenorphine administration is accompanied with speedy-acting antidepressant effects.
Objective: To describe the antidepressant potentials of buprenorphine.
Discussion: Buprenorphine has rapid-acting and continuous antidepressant properties. Buprenorphine intake is associated with enhanced psychoactivity and demotion in depression. Regulation of mood and emotion are seen following buprenorphine administration. Most of the time buprenorphine is well tolerated.
Conclusion: Buprenorphine use can be safe and has fast-acting and continuous antidepressant effects.